Summary of the characteristics of the included head-to-head studies.

BCVA = best corrected visual acuity; CATT = comparison of age related macular degeneration treatment trials; HARBOR = the phase III, double-masked, multicenter, randomized active treatment-controlled study of the efficacy and safety of 0,5 mg and 2,0 mg ranibizumab administered monthly or on an as-needed basis in patients with subfoveal neovascular age-related macular degeneration; IVAN = inhibit VEGF in age related choroidal neovascularisation; OCT = optical coherence tomography; PRN = pro re nata; SD = spectral domain, TD = time domain.*In CATT, patients were assigned equally to 1 of 4 treatment groups defined by drug (ranibizumab or bevacizumab) and by dosing regimen at enrollment. At 1 year, patients initially assigned to monthly treatment retained their drug assignment but were reassigned randomly, with equal probability, to either monthly or PRN treatment. Patients initially assigned to PRN had no change in assignment.**22.6% of the scans in the 2nd year with SD-OCT.Summary of the characteristics of the included head-to-head studies.